|
Age (year), median (range)
|
47.35 ± 3.97 (40–55)
|
≥ 0.05
|
|
Smoking, n (%)
| |
≥ 0.05
|
|
Yes
|
7(5%)
| |
|
No
|
135(95%)
| |
|
BMI, median (range)
|
25.03 ± 2.1(20–32)
|
≥ 0.05
|
|
Follow-up (months), median (range)
|
16.5 ± 3.73(12–24)
|
≥ 0.05
|
|
Menopausal status, n (%)
| |
≥ 0.05
|
|
Premenopausal
|
47(33%)
| |
|
Post-menopausal
|
95(67%)
| |
|
Stage of disease, n (%)
| |
≤ 0.05
|
|
IIB
|
19(13%)
| |
|
IIIA
|
31(22%)
| |
|
IIIB
|
39(28%)
| |
|
IIIC
|
53(37%)
| |
|
Tumor classification, n (%)
| |
≤ 0.001
|
|
T1
|
0
| |
|
T2
|
0
| |
|
T3
|
36(25%)
| |
|
T4
|
106(75%)
| |
|
Lymph node status, n (%)
| |
≤ 0.05
|
|
N0
|
0
| |
|
N1
|
48(34%)
| |
|
N2/N3
|
94(66%)
| |
|
ER, PR status at initial diagnosis, n (%)
| |
≥ 0.05
|
|
Positive
|
90(63.4%)
| |
|
Negative
|
52(33.6%)
| |
|
HER-2 status at initial diagnosis
| |
≥ 0.05
|
|
Positive
|
41(28.9%)
| |
|
Negative
|
101(71.1%)
| |
|
Surgical margin status, n (%)
| |
≥ 0.05
|
|
Positive
|
2(1%)
| |
|
Negative
|
140(99%)
| |
|
Skin invasion and ulceration, n (%)
| | |
|
Yes
|
106(75%)
| |
|
No
|
36(25%)
| |
|
Pectoralis major
| | |
|
Yes
|
53(37%)
| |
|
No
|
89(63%)
| |
|
Histological type, n (%)
| | |
|
Infiltrating ductal carcinoma
|
138(97%)
| |
|
Inflammatory
|
4(3%)
| |
|
Molecular subtyping, n (%)
| |
≤ 0.05
|
|
Luminal A
|
38(26.8%)
| |
|
Luminal B
|
52(36.6%)
| |
|
Triplenegative
|
31(21.8%)
| |
|
HER-2 overexpression
|
21(14.8%)
| |
